With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s ...

Paul Hudson has a blunt view of peers who hand off the execution of their artificial intelligence strategy to their chief ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less-than-expected benefit in a late-stage trial.After 24 weeks of treatment, ...

A long-coveted deal to slash US steel and aluminium tariffs to zero has been shelved on the eve of Donald Trump’s state visit ...

Sanofi ( NASDAQ: SNY) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT ...

Sentiment soured in May when Sanofi reported the failure of a phase 3 trial of its Regeneron-partnered IL-33 drug candidate ...

Rabat — Multinational pharmaceutical and healthcare company Sanofi has announced the appointment of Rami Mroueh as chairman ...